Back to Search
Start Over
[Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa].
- Source :
-
Bulletin du cancer [Bull Cancer] 2019 Apr; Vol. 106 (4), pp. 354-370. Date of Electronic Publication: 2019 Mar 06. - Publication Year :
- 2019
-
Abstract
- Faced to an undetermined ovarian mass on ultrasound, an MRI is recommended and the ROMA score (combining CA125 and HE4) can be proposed (grade A). In case of suspected early stage ovarian or fallopian tube cancer, omentectomy (at least infracolonic), appendectomy, multiple peritoneal biopsies, peritoneal cytology (grade C) and pelvic and para-aortic lymphadenectomy are recommended (grade B) for all histological types, except for the expansive mucinous subtype where lymphadenectomy may be omitted (grade C). Minimally invasive surgery is recommended for early stage ovarian cancer, if there is no risk of tumor rupture (grade B). Adjuvant chemotherapy with carboplatin and paclitaxel is recommended for all high-grade ovarian or Fallopian tube cancers, stage FIGO I-IIA (grade A). In case of ovarian, Fallopian tube or primitive peritoneal cancer of FIGO III-IV stages, thoraco-abdomino-pelvic CT scan with injection (grade B) is recommended. Laparoscopic exploration for multiple biopsies (grade A) and to evaluate carcinomatosis score (at least using the Fagotti score) (grade C) are recommended to estimate the possibility of a complete surgery (i.e. no macroscopic residue). Complete medial laparotomy surgery is recommended for advanced cancers (grade B). It is recommended in advanced cancers to perform para-aortic and pelvic lymphadenectomy in case of clinical or radiological suspicion of metastatic lymph node (grade B). In the absence of clinical or radiological lymphadenopathy and in case of complete peritoneal surgery during an initial surgery for advanced cancer, it is possible not to perform a lymphadenectomy because it does not modify the medical treatment and the overall survival (grade B). Primary surgery is recommended when no tumor residue is possible (grade B). After a complete first surgery, it is recommended to deliver 6 cycles of intravenous (grade A) or to propose intraperitoneal (grade B) chemotherapy, to be discussed with patient, according to the benefit/risk ratio. After a complete interval surgery for a FIGO III stage, the hyperthermic intra peritoneal chemotherapy (HIPEC) can be proposed in the same conditions of the OV-HIPEC trial (grade B). In case of tumor residue after surgery or FIGO stage IV, chemotherapy associated with bevacizumab is recommended (grade A).<br /> (Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Subjects :
- Antineoplastic Agents therapeutic use
Bevacizumab therapeutic use
Chemotherapy, Adjuvant
Female
France
Humans
Hyperthermia, Induced
Lymph Node Excision
Magnetic Resonance Imaging
Phthalazines therapeutic use
Piperazines therapeutic use
Societies, Medical
Ultrasonography
Carcinoma, Ovarian Epithelial diagnostic imaging
Carcinoma, Ovarian Epithelial drug therapy
Carcinoma, Ovarian Epithelial pathology
Carcinoma, Ovarian Epithelial surgery
Fallopian Tube Neoplasms diagnostic imaging
Fallopian Tube Neoplasms drug therapy
Fallopian Tube Neoplasms pathology
Fallopian Tube Neoplasms surgery
Ovarian Neoplasms diagnostic imaging
Ovarian Neoplasms drug therapy
Ovarian Neoplasms pathology
Ovarian Neoplasms surgery
Peritoneal Neoplasms diagnostic imaging
Peritoneal Neoplasms drug therapy
Peritoneal Neoplasms pathology
Peritoneal Neoplasms surgery
Subjects
Details
- Language :
- French
- ISSN :
- 1769-6917
- Volume :
- 106
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Bulletin du cancer
- Publication Type :
- Academic Journal
- Accession number :
- 30850152
- Full Text :
- https://doi.org/10.1016/j.bulcan.2019.01.014